irinotecan has been researched along with azd4547 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gao, B; Gao, Z; Gavine, PR; Ji, J; Ji, Q; Kilgour, E; Liu, K; Shen, D; Su, X; Tang, L; Xie, L; Xu, Y; Yin, X; Zhang, J; Zhang, L; Zhang, X; Zhou, M | 1 |
1 other study(ies) available for irinotecan and azd4547
Article | Year |
---|---|
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Synergism; Female; Fluorouracil; Gene Amplification; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2013 |